Sintx Technologies (NASDAQ:SINT – Get Rating) and Arch Therapeutics (OTCMKTS:ARTH – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.
Risk and Volatility
Sintx Technologies has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Arch Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.
Insider and Institutional Ownership
3.1% of Sintx Technologies shares are held by institutional investors. Comparatively, 0.0% of Arch Therapeutics shares are held by institutional investors. 1.0% of Sintx Technologies shares are held by company insiders. Comparatively, 9.7% of Arch Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sintx Technologies | 0 | 0 | 1 | 0 | 3.00 |
| Arch Therapeutics | 0 | 0 | 0 | 0 | N/A |
Sintx Technologies presently has a consensus target price of $136.00, suggesting a potential upside of 8,507.59%. Given Sintx Technologies’ higher probable upside, analysts plainly believe Sintx Technologies is more favorable than Arch Therapeutics.
Profitability
This table compares Sintx Technologies and Arch Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sintx Technologies | -771.24% | -115.71% | -72.18% |
| Arch Therapeutics | -32,842.03% | N/A | -301.47% |
Earnings and Valuation
This table compares Sintx Technologies and Arch Therapeutics’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sintx Technologies | $1.56 million | 0.55 | -$12.04 million | N/A | N/A |
| Arch Therapeutics | $20,000.00 | 213.36 | -$5.28 million | N/A | N/A |
Arch Therapeutics has lower revenue, but higher earnings than Sintx Technologies.
Summary
Sintx Technologies beats Arch Therapeutics on 7 of the 11 factors compared between the two stocks.
About Sintx Technologies
SINTX Technologies, Inc. engages in the development and commercialization of silicon nitride for medical and non-medical applications. It markets spinal fusion products and develops products for use in total hip and knee joint replacements. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in 1996 and is headquartered in Salt Lake City, UT.
About Arch Therapeutics
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.
Receive News & Ratings for Sintx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sintx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
